HopeStage
Back to all studies
CompletedNCT00395031

Ziprasidone and blood sugar and fats in people with diabetes and schizophrenia

About this titleRead the official source — NCT00395031
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
New YorkSee all locations and recruitment
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateSeptember 2003
Recruitment status
Completed
Enrollment listed in the registry
57
Sponsor
Manhattan Psychiatric Center
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00395031
Official title
Show the full official title

The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New York

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Manhattan Psychiatric Center.

Did this study involve medication?

Yes. The study involved medication, including Ziprasidone.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies